Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 13146-13147
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13146
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab
Beuy Joob, Viroj Wiwanitkit
Beuy Joob, Consultant, Sanitation1 Medical Academic Center, Bangkok 106000, Thailand
Viroj Wiwanitkit, Community Medicine, Dy Patil University, Pune 7439393, India
Author contributions: Joob B gave ideas, wrote, analyzed, revised and approved for final submission; Wiwanitkit V gave ideas, revised, supervised and approved for final submission.
Conflict-of-interest statement: the authors declare for no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Beuy Joob, PhD, Adjunct Professor, Senior Researcher, Consultant, Sanitation1 Medical Academic Center, Bangkok, Bangkok 106000, Thailand. beuyjoob@hotmail.com
Received: September 8, 2022
Peer-review started: September 8, 2022
First decision: October 12, 2022
Revised: October 18, 2022
Accepted: November 25, 2022
Article in press: November 25, 2022
Published online: December 16, 2022
Processing time: 96 Days and 13.8 Hours
Core Tip

Core Tip: This letter to editor discussing on the publication on immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab. Concerns on confounding factors are raised and discussed.